I'm LongbridgeAI, I can summarize articles.Scancell published a corporate deck outlining its iSCIB1+ melanoma vaccine program ahead of a planned Phase 3 trial in H2 2026. The registrational study will evaluate the combination with ipilimumab and nivolumab in first-line advanced melanoma, targeting 550 patients with progression-free survival as the primary endpoint. Positive Phase 2b data showed superior PFS compared to CheckMate 067. Regulatory milestones include FDA IND clearance in Jan 2026 and potential Fast Track designation. Scancell estimates global peak sales up to USD 9 billion.
- Scancell outlined plans to start a global Phase 3 study of iSCIB1+ with ipilimumab, nivolumab in first-line advanced melanoma in H2 2026. * Phase 3 design: double-blind, randomized, registrational trial; 550 patients; primary endpoint progression-free survival; overall survival secondary. * Phase 2b SCOPE update: 77% progression-free survival at 22 months versus 43% for ipilimumab, nivolumab in CheckMate 067 cross-trial comparison. * Regulatory timeline: FDA IND clearance in Jan 2026; Fast Track designation in Apr 2026; potential accelerated approval decision point tied to H2 2028 PFS readout. * Company estimated global peak sales potential up to USD 9 billion across advanced melanoma and earlier-stage settings. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Scancell Holdings plc published the original content used to generate this news brief on July 23, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here